Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
Endres, Christopher J; Salinger, David H; Köck, Kathleen; Gastonguay, Marc R; Martin, David A; Klekotka, Paul; Nirula, Ajay; Gibbs, Megan A.
J Clin Pharmacol
; 54(11): 1230-8, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24846347
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review.
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use.
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
A novel microgel complex delivers acne medicine deep into follicles while demonstrating high patient tolerance.
Observance: Définitions et méthodes de mesure: spécificités de l'observance des traitements topiques.
Topical preparations and their use in dermatology.